Ito Taihei, Kenmochi Takashi, Kurihara Kei, Aida Naohiro
Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, Dengakugakubo 1-98, Kutsukakecho, Toyoake 470-1192, Japan.
J Clin Med. 2022 Mar 16;11(6):1645. doi: 10.3390/jcm11061645.
Islet transplantation shows the promise of being capable of relieving glucose instability and improving QOL of patients with type 1 diabetes that cannot be controlled due to severe hypoglycemia unawareness. In Japan, following the first human islet isolation from a donor after cardiac death in 2003 and the first clinical islet transplantation in 2004, islet transplantation was performed for the improvement of type 1 diabetes as a single-center trial in several centers. Although it was discontinued due to the possibility of contamination of collagenase by bovine brain component in 2007, the phase II clinical trial of islet transplantation started using ATG induction and a TNF-α inhibition protocol in 2012. The primary endpoints of this trial were the proportion of patients with HbA1c < 7.4% and freedom from severe hypoglycemic events at one year after the first islet cell infusion. In an interim analysis, this endpoint was achieved in 75% of cases. In April 2020, clinical islet transplantation was finally covered by health insurance in Japan, thanks to these outcomes. We herein introduce more than 20 years of history of clinical islet transplantation in Japan.
胰岛移植显示出有望缓解血糖不稳定,并改善因严重低血糖无意识而无法控制的1型糖尿病患者的生活质量。在日本,自2003年首次从心脏死亡后的供体中分离出人类胰岛,以及2004年首次进行临床胰岛移植后,胰岛移植在多个中心作为单中心试验用于改善1型糖尿病。尽管由于2007年胶原酶可能被牛脑成分污染而停止,但2012年开始了使用抗胸腺细胞球蛋白诱导和肿瘤坏死因子-α抑制方案的胰岛移植II期临床试验。该试验的主要终点是首次胰岛细胞输注后一年时糖化血红蛋白(HbA1c)<7.4%的患者比例以及无严重低血糖事件。在中期分析中,75%的病例达到了这一终点。由于这些结果,2020年4月,临床胰岛移植最终在日本被纳入医保。我们在此介绍日本临床胰岛移植20多年的历史。